Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Multi-kinase inhibitor (VEGFR/PDGFR/c-KIT)

Pazopanib (Specialist drug)

Brand names: Votrient

Pazopanib is a specialist oral multi-targeted tyrosine kinase inhibitor used in the treatment of advanced renal cell carcinoma and selected soft tissue sarcomas.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It inhibits multiple receptor tyrosine kinases including VEGFR, PDGFR and c-KIT, blocking tumour angiogenesis and cell proliferation.

Prescribing in practice

  • Severe and potentially fatal hepatotoxicity can occur, so liver function must be checked at baseline and monitored regularly during treatment.
  • It can cause hypertension, QT prolongation, arterial and venous thrombotic events and impaired wound healing, so it should be stopped before surgery.
  • It is metabolised by CYP3A4 and absorption is reduced by acid-suppressing drugs and food, so it should be taken without food and away from such medicines.

Monitoring

Monitor liver function, blood pressure and ECG where indicated throughout treatment.

Counselling the patient

  • Take on an empty stomach and report yellowing of the skin or eyes, dark urine or unusual tiredness.
  • Tell your team before any planned surgery and report severe headache or high blood pressure symptoms.

Evidence & guidelines

Use in renal cell carcinoma and soft tissue sarcoma is supported by NICE guidance and pivotal randomised trials.

Reference: NICE TA215/TA465; SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways